|
The market for therapeutic apoptosis modulators is currently only emerging. However, over the five-year time course of this analysis, significant progress is anticipated with respect to the realization of the incredible potential offered by certain apoptosis modulators.
Theta’s report focuses on a complete description of advances made in developing and bringing therapeutic apoptosis modulators to markets worldwide and includes an analysis of probable future developments in the treatment of variety of diseases and conditions such as, cancer, cardiovascular disease, autoimmune diseases, infectious diseases, Alzheimer’s disease, Parkinson’s disease, HIV/AIDS, and organ transplant rejection.
Major therapeutic targets of apoptosis-based compounds discussed in the report include:
- Caspase activators and inhibitors
- Bcl-2 modulators
- p53 modulators
- Inhibitors of apoptosis proteins (IAPs)
- Protein kinase pathway modulators
- Mixed lineage kinase inhibitor
- Multiple signal transduction regulators
Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Competitor Analysis: TGF-R Agonists and Antagonists
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Strategic Analysis of the Bladder Cancer Therapeutics
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report
|
(0 items)
